Overview

Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients

Status:
Completed
Trial end date:
2008-12-30
Target enrollment:
0
Participant gender:
All
Summary
Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. We are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Dexmedetomidine
Criteria
Inclusion Criteria:

- pediatric patient

- >25% total body surface area (tbsa) burn and < 90% tbsa

- opioid requirements > 0.1 mg/kg/hour of morphine (or equivalent)

- midazolam requirement > 0.1 mg/kg/hour

- treatment team determined that patient should be started on dexmedetomidine

Exclusion Criteria:

- hemodynamically unstable patients (epinephrine > 1.0 ug/kg/min, levophed > 0.75
ug/kg/min, dopamine > 10 ug/kg/min)

- pregnant patients

- patients with history of heart block

- patients with congenital heart disease

- patients with significant hepatic dysfunction

- patients with urine output < 0.5 ml/kg/hour [averaged] over past 24 hours